US FDA Advisers Recommend New Target for 2024-25 COVID Shot Campaign

Wednesday, 5 June 2024, 16:31
In a recent development, US FDA advisers have suggested shifting the focus of COVID shot campaigns to target variants with the JN.1 lineage in 2024-25. This decision aims to enhance the effectiveness of vaccinations against emerging strains and provide better protection for the population. The recommendation comes as part of the ongoing efforts to combat the evolving landscape of the pandemic.
https://store.livarava.com/633145ef-2373-11ef-a40d-9d5fa15a64d8.jpg
US FDA Advisers Recommend New Target for 2024-25 COVID Shot Campaign

US FDA Advisers Recommend New Target for 2024-25 COVID Shot Campaign

In a recent development, US FDA advisers have suggested shifting the focus of COVID shot campaigns to target variants with the JN.1 lineage in 2024-25.

Enhanced Protection Against Emerging Strains

  • Improved Effectiveness: By adapting vaccination strategies to target specific variants, the aim is to provide better protection against the evolving landscape of the virus.

The recommendation comes as part of the ongoing efforts to combat the unpredictable nature of the COVID-19 pandemic.

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe